For HCPs Only
Recent Clinical Updates
Loading latest clinical updates

Clinical Intelligence & Drug Records for US-Licensed Practitioners

The integrated, institutional-grade registry trusted by US-licensed practitioners for evidence-based clinical data, drug information, and peer-reviewed drug updates.

Drug Update Briefing

Weekly drug approvals, safety updates, and specialty coverage for healthcare professionals.

Clinical Resources

Drug updates, reference data, and specialist-led coverage.

Recent Clinical Updates

Latest Drug & Specialty Updates

View All

Specialty Coverage

Therapeutic-area updates for clinical review.

All Specialties

Drug Information

FDA drug records and prescribing context.

Review drug records, NDC references, dosage tools, and interaction resources alongside clinical coverage.

FDA data

Drug Reference

Drug approvals, labels, and clinical context.

Access structured FDA label data, dosage references, NDC records, interactions, and prescribing context.

Clinical Coverage

Additional Drug Updates

Pediatrics

FDA Approves Nirsevimab for RSV Prevention in Infants: MELODY Trial

2h ago|3 min read|By Dr. Aditya Kumar
Cardiology

FDA Approves Empagliflozin for HFpEF: 21% Reduction in CV Events

2h ago|3 min read|By Dr. Arjun Sharma
Oncology

FDA Approves Pembrolizumab for High-Risk Early-Stage TNBC: 63% pCR in KEYNOTE-522

2h ago|3 min read|By Dr. Rahul Verma
Nephrology

FDA Approves Finerenone for Chronic Kidney Disease: 18% Risk Reduction in FIDELIO-DKD Trial

2h ago|3 min read|By Dr. Praveen Singh
Pain Management

FDA Approves Suzetrigine for Acute Pain: First Non-Opioid Option

2h ago|3 min read|By Dr. Abhishek Malhotra
Endocrinology

FDA Approves Semaglutide for Cardiovascular Risk: 20% MACE Reduction in Adults with Obesity

3h ago|3 min read|By Dr. Amit Desai
Hematology

CAR-T Cell Therapy Shows Promising Outcomes for DLBCL and Multiple Myeloma in 2024

3h ago|3 min read|By Dr. Shruti Pandey
Otolaryngology

FDA Approves Lunsotogene Parvec-Cwha for Genetic Hearing Loss: First Gene Therapy for OTOF Variants

3h ago|2 min read|By Editorial Team
Neurology

FDA Approves Lecanemab for Alzheimer: Weekly Dosing to Enhance Treatment Adherence

3h ago|3 min read|By Dr. Vikram Patel
Endocrinology

FDA Approves Orforglipron for Weight Loss: Oral GLP-1 Option for Obesity

3h ago|3 min read|By Dr. Amit Desai
Endocrinology

WHO Updates GLP-1 Guidelines: Tirzepatide and Semaglutide for Obesity Management

3h ago|3 min read|By Dr. Amit Desai
Hematology

FDA Approves Narsoplimab for TA-TMA: First Treatment for Stem Cell Transplant Complication

3h ago|3 min read|By Dr. Shruti Pandey
Oncology

WHO Updates Guidelines on BRCA Testing for Breast and Ovarian Cancer: Key Screening Recommendations

May 1|3 min read|By Dr. Rahul Verma
Endocrinology

FDA Approves Tirzepatide for Weight Management: Dosing Differences Between Mounjaro and Zepbound

May 1|3 min read|By Dr. Amit Desai
Neurology

CGRP Inhibitors: Erenumab, Fremanezumab, and Galcanezumab for Migraine Prevention

May 1|3 min read|By Dr. Aditi Kulkarni
Neurology

FDA Approves Zycubo for Menkes Disease: 78% Reduction in Mortality Risk

May 1|3 min read|By Dr. Aditi Kulkarni
Pulmonology

FDA Approves Depemokimab for Severe Asthma: Once-Yearly Injection for Eosinophilic Phenotype

May 1|3 min read|By Dr. Nikhil Chatterjee
Hematology

FDA Approves Fitusiran for Hemophilia: Antithrombin Lowering Therapy for Patients 12 and Older

May 1|3 min read|By Dr. Shruti Pandey
Dermatology

FDA Approves Bimekizumab for Moderate to Severe Plaque Psoriasis: BE VIVID Trial Results

Apr 30|3 min read|By Dr. Divya Agarwal
Otolaryngology

FDA Approves Dupilumab for Allergic Fungal Rhinosinusitis: First Indication for AFRS

Apr 30|3 min read|By Editorial Team
Endocrinology

FDA Submits NDA for CagriSema: Fixed-Dose Combination of Cagrilintide and Semaglutide for Obesity Management

Apr 30|3 min read|By Dr. Amit Desai
Oncology

WHO Updates Guidelines on BRCA Testing for Breast and Ovarian Cancer Screening

Apr 30|3 min read|By Dr. Meera Pillai
Neurology

FDA Approves Ofatumumab and Natalizumab for High Efficacy in Multiple Sclerosis Treatment

Apr 30|3 min read|By Dr. Vikram Patel